Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 4/20 | 0.34 |
| ▸ | CTSL | P07711 | 3/20 | 0.34 |
| ▸ | CTSK | P43235 | 3/20 | 0.33 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.32 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3019936 | 1.00 | CTSS (0.34) | CTSSCTSLCTSKCACNA2D1CACNB3 | |
| SCHEMBL3019938 | 1.00 | CTSS (0.34) | CTSSCTSLCTSKCACNA2D1CACNB3 | |
| SCHEMBL2637586 | 0.79 | CACNA2D1 (0.45) | CTSSCTSLCTSKCACNA2D1CACNB3 | |
| SCHEMBL16576 | 0.79 | CACNA2D1 (0.45) | CTSSCTSLCTSKCACNA2D1CACNB3 | |
| SCHEMBL16694 | 0.79 | CACNA2D1 (0.45) | CTSSCTSLCTSKCACNA2D1CACNB3 | |
| Ammonia Solution, Strong SCHEMBL3024172 | 0.77 | CACNA2D1 (0.44) | CTSSCTSLCTSKCACNA2D1CACNB3 | |
| SCHEMBL262562 | 0.77 | CACNA2D1 (0.44) | CTSSCTSLCTSKCACNA2D1CACNB3 | |
| Ammonia Solution, Strong SCHEMBL3024177 | 0.77 | CACNA2D1 (0.44) | CTSSCTSLCTSKCACNA2D1CACNB3 | |
| SCHEMBL262563 | 0.77 | CACNA2D1 (0.44) | CTSSCTSLCTSKCACNA2D1CACNB3 | |
| Tert-Butylamine SCHEMBL4158435 | 0.75 | CACNA2D1 (0.43) | CTSSCTSLCTSKCACNA2D1CACNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304252-B2 | Stereoselective bioconversion of aliphatic dinitriles into cyano carboxylic acids | PFIZER INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-20100204503-A1 | Stereoselective Bioconversion of Aliphatic Dinitriles into Cyano Carboxylic Acids | PFIZER INC | 2010-08-12 | — | — | US | disclosed |
| US-7727749-B2 | Stereoselective bioconversion of aliphatic dinitriles into cyano carboxylic acids | PFIZER, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20070196905-A1 | Stereoselective bioconversion of aliphatic dinitriles into cyano carboxylic acids | PFIZER INC. | 2007-08-23 | — | — | US | disclosed |
| EP-1745136-A1 | STEREOSELECTIVE BIOCONVERSION OF ALIPHATIC DINITRILES INTO CYANO CARBOXYLIC ACIDS | Pfizer Products Inc. (US) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005100580-A1 | STEREOSELECTIVE BIOCONVERSION OF ALIPHATIC DINITRILES INTO CYANO CARBOXYLIC ACIDS | PFIZER PRODUCTS INC. (US) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070196905-A1 | Stereoselective bioconversion of aliphatic dinitriles into cyano carboxylic acids | GABRD, GABRB3, GABRB2 | CTSS 3094/4885CTSL 2939/4885CTSK 4143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.